Therapeutic area intelligence for Prostacyclin Analog with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

United Therapeutics →

Assets

BELOTECA →

Tyvaso →

Recent signals(2)

RegulatoryJuly 16, 2026

FDA Grants Approval for ILOPROST ANDA214997 by BELOTECA

The FDA has granted approval for the ANDA214997 application for ILOPROST submitted by BELOTECA.

RegulatoryJune 6, 2026

FDA Accepts Supplement Application for Tyvaso (Treprostinil)

The FDA has accepted a supplemental application for Tyvaso, an inhaled formulation of treprostinil.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.